Royalty Pharma (RPRX) Financials: Revenue & Earnings
RPRX$65.93+1.11 +1.71%
$29.36B
Market Cap
26.89
P/E
12.39
Forward P/E
51
Score
Royalty Pharma (RPRX) Financials: Revenue & Earnings
RPRX price $65.93 +1.11 +1.71%
- Ticker
- RPRX
- Price
- $65.93
- Change
- +1.11 +1.71%
- Market cap ?
- $29.36B
- P/E ?
- 26.89
- Forward P/E ?
- 12.39
- Dividend yield ?
- 1.43%
- Beta ?
- 0.41
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Stocklytics score
- 51
- Value
- 47
- Quality
- 68
- Growth
- 39
Stocklytics score rationale: value 47, quality 68, growth 39.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 1877410000 | 1597930000 | 1794894000 | 1814254000 | 2122353000 | 2289463000 | 2237215000 | 2354554000 | 2263576000 | 2378193000 |
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was…
Earnings and financials
Royalty Pharma plc (RPRX) trades at $65.93, with a market cap of $29.36B and a trailing P/E of 26.89. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 1877410000 | 1597930000 | 1794894000 | 1814254000 | 2122353000 | 2289463000 | 2237215000 | 2354554000 | 2263576000 | 2378193000 |
Insights · Dividends · Forecast · Financials · Learn